# Crescent Biopharma Inc. (CBIO) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $20.88, market value $776 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Crescent Biopharma Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 71.5×**. Each dollar of revenue is priced at 71.5×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 4.4×**. The shares trade at 4.4× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -9.5%** (5-yr avg -0.4%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -75.8%**. Return on equity is negative because earnings are negative.
- **Return on assets: -64.1%**. Each dollar of assets produces -64.1% of profit.

## Financial health
- **Current ratio: 6.56** (quick 6.56). Current assets cover the next year's liabilities 6.56 times.
- **Altman Z-score: 12.62**. A Z-score of 12.62 places the company in the safe zone for bankruptcy risk.

## Dividends
- **Dividend: none**. Crescent Biopharma Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover Crescent Biopharma Inc.; the consensus is strong_buy, with an average price target of $30.60 (+47% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 52.5%** (YTD 76.1%, 3-mo 16.0%). The shares are up 52.5% over twelve months including dividends.
- **From 52-week high: -23.8%** (139.4% above the low). Trading 24% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 68**. An RSI of 68 is neutral.
- **Beta (1 yr): 0.97** (volatility 80%). Beta of 0.97 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CBIO · Page: https://foliofundamentals.com/stocks/cbio

Not investment advice.